-
On October 10, 2025, President Donald Trump announced a deal with AstraZeneca to lower drug prices for Medicaid patients by matching the lowest prices in developed countries. The agreement includes AstraZeneca's commitment to invest $50 billion in U.S. manufacturing by 2030 and participation in the upcoming TrumpRx website, which will sell discounted drugs directly to consumers starting in early 2026.
-
North Carolina's medical debt cancellation program, launched 15 months ago, has helped nearly a quarter of residents, erasing an average of $2,600 per person. The initiative, part of broader Medicaid incentives, has surpassed initial estimates, with hospitals removing debt from credit reports and aiding millions in financial recovery.
-
As of November 2025, US schools and universities face escalating conflicts over antisemitism and diversity, equity, and inclusion (DEI) policies. California confronts a federal lawsuit challenging a new law aimed at combating antisemitism in schools. Universities like UVA and UCLA negotiate with the federal government over DEI bans and antisemitism probes, while K-12 schools report rising antisemitic harassment since 2023.
-
Liberia's government announced a significant increase in medicine procurement, with $10 million allocated for 2024-2025. The initiative aims to reduce drug shortages, improve accountability, and strengthen healthcare access nationwide, supported by government leadership and community involvement.
-
As of December 2025, the WHO has issued its first guidelines recommending long-term use of GLP-1 medications like Wegovy and Mounjaro for obesity treatment, recognizing obesity as a chronic disease. The US government has negotiated significant price cuts for these drugs, expanding Medicare and Medicaid coverage to more patients. However, concerns remain about drug accessibility, side effects, and weight regain after stopping treatment.